A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7A) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers.

Trial Profile

A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7A) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2012

At a glance

  • Drugs Candida vaccine (Primary)
  • Indications Vulvovaginal candidiasis
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Oct 2012 Planned End Date changed from 1 Apr 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 12 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top